CMFRI develops anti-obesity nutraceutical

For commercial production of Cadalmin

May 28, 2017 08:21 am | Updated 08:21 am IST - KOCHI

The anti-obesity nutraceutical developed by the Central Marine Fisheries Research Institute (CMFRI) from seaweeds will soon hit the market.

The CMFRI has signed a pact with healthcare group VLCC for the commercial production of the product named Cadalmin Antihypercholesterolemic extract (Cadalmin - ACe), a natural remedy for obesity. A. Gopalakrishnan, director of CMFRI, signed a licence agreement with the director and executive vice president of the firm, said a release. Cadalmin was developed using natural marine bioactive ingredients from selected seaweeds.

Top News Today


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.